We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+3.24%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$218M
AUM Growth
-$7.72M
Cap. Flow
-$8.98M
Cap. Flow %
-4.12%
Top 10 Hldgs %
95.32%
Holding
13
New
1
Increased
6
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$3.42M
2
EXEL icon
Exelixis
EXEL
+$2.47M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$1.71M
4
BNTX icon
BioNTech
BNTX
+$1.12M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$871K

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$10.2M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.5M
3
BIIB icon
Biogen
BIIB
+$2.23M
4
CAH icon
Cardinal Health
CAH
+$1.83M
5
MURA
Mural Oncology
MURA
+$47.7K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.3B
$37.7M 17.31%
1,677,393
+111,253
+7% +$2.47M
UTHR icon
2
United Therapeutics
UTHR
$25.8B
$37.7M 17.29%
118,208
-38,506
-25% -$10.2M
BIIB icon
3
Biogen
BIIB
$30B
$28.7M 13.18%
123,785
-10,283
-8% -$2.23M
TARO
4
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$28M 12.83%
650,089
+2,221
+0.3% +$94.3K
CAH icon
5
Cardinal Health
CAH
$53.9B
$21.4M 9.83%
217,656
-18,000
-8% -$1.83M
ENTA icon
6
Enanta Pharmaceuticals
ENTA
$366M
$16.2M 7.45%
1,251,338
+126,752
+11% +$1.71M
JAZZ icon
7
Jazz Pharmaceuticals
JAZZ
$15.9B
$11.6M 5.35%
109,076
+7,925
+8% +$871K
BNTX icon
8
BioNTech
BNTX
$22.9B
$10.6M 4.88%
132,293
+12,293
+10% +$1.12M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$78.5B
$8.25M 3.79%
7,853
-4,641
-37% -$4.5M
SNY icon
10
Sanofi
SNY
$103B
$7.46M 3.43%
153,832
+2,873
+2% +$139K
ALKS icon
11
Alkermes
ALKS
$8.22B
$6.21M 2.85%
257,554
– –
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$307M
$3.74M 1.72%
+662,166
New +$3.42M
MURA
13
DELISTED
Mural Oncology
MURA
$236K 0.11%
75,057
-12,944
-15% -$47.7K

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Krensavage Asset Management held 13 positions worth $218M, down 3.4% from $226M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Krensavage Asset Management withdrew a net $8.98M in Q2 2024, reducing 5 holdings. Its largest reduction was United Therapeutics, cutting an estimated $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Krensavage Asset Management opened a new position in Vanda Pharmaceuticals worth $3.74M.

  • Krensavage Asset Management's largest Q2 2024 buy was Vanda Pharmaceuticals: 662,166 shares worth $3.74M.
  • Krensavage Asset Management added most to Exelixis in Q2 2024, an estimated $2.47M increase.
  • Krensavage Asset Management's biggest Q2 2024 reduction was United Therapeutics, cutting an estimated $10.2M.
  • Krensavage Asset Management's ten largest holdings make up 95% of its $218M portfolio in Q2 2024.
  • Krensavage Asset Management opened 1 new position and closed 0 in Q2 2024.
  • Krensavage Asset Management's portfolio value fell 3.4% quarter-over-quarter to $218M.

Based on Krensavage Asset Management's 13F filing for Q2 2024, filed 15 Aug 2024.